Exagen Inc XGN.OQ XGN.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Vista California-based company is expected to report a 1.1% increase in revenue to $13.565 million from $13.42 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Exagen Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Exagen Inc is $6.00, above its last closing price of $2.60.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.34 | -0.34 | -0.16 | Beat | 53.6 |
Mar. 31 2024 | -0.36 | -0.36 | -0.19 | Beat | 47.5 |
Dec. 31 2023 | -0.40 | -0.43 | -0.31 | Beat | 28.5 |
Sep. 30 2023 | -0.46 | -0.47 | -0.31 | Beat | 34 |
Jun. 30 2023 | -0.50 | -0.49 | -0.28 | Beat | 43.4 |
Mar. 31 2023 | -0.57 | -0.56 | -0.44 | Beat | 21.7 |
Dec. 31 2022 | -0.81 | -0.78 | -0.83 | Missed | -6.4 |
Sep. 30 2022 | -0.73 | -0.73 | -0.47 | Beat | 35.6 |
This summary was machine generated November 8 at 16:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。